{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:21:16Z","timestamp":1778541676799,"version":"3.51.4"},"reference-count":7,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>A novel approach to high\u2010throughput, targeted liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS) analysis has been developed. A single chromatographic system can be used for the analysis of a range of 20 drugs and metabolites with a total analysis time of 36\u00a0s (one 96\u2010well plate of prepared samples per hour). To demonstrate the applicability of this approach to quantitative analysis, a method has been validated for the therapeutic drug monitoring of clozapine and norclozapine following automated extraction from human plasma. Chromatographic retention times were 11.4 and 12.4\u00a0s for norclozapine and clozapine, respectively (for both analytes the chromatographic peak width was less than 1\u00a0s). Comparison with a conventional LC\u2013MS\/MS method (5 min analysis time) showed excellent agreement. This new approach offers analysis times more akin to flow\u2010injection analysis, but is likely to be more widely applicable because of chromatographic resolution from residual matrix components and isobaric interferences.<\/jats:p>","DOI":"10.1002\/dta.2223","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T23:56:49Z","timestamp":1496707009000},"page":"323-329","source":"Crossref","is-referenced-by-count":25,"title":["Ultra\u2010fast LC\u2013MS\/MS in therapeutic drug monitoring: Quantification of clozapine and norclozapine in human plasma"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-7886","authenticated-orcid":false,"given":"Lewis","family":"Couchman","sequence":"first","affiliation":[{"name":"Viapath Analytics, Toxicology Unit Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust  London UK"},{"name":"Pharmaceutical Sciences Clinical Academic Group King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle S.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Viapath Analytics, Toxicology Unit Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krithika","family":"Subramaniam","sequence":"additional","affiliation":[{"name":"Viapath Analytics, Toxicology Unit Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A.","family":"Handley","sequence":"additional","affiliation":[{"name":"Viapath Analytics, Toxicology Unit Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Boughtflower","sequence":"additional","affiliation":[{"name":"GSK  Hertfordshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Benton","sequence":"additional","affiliation":[{"name":"Agilent Technologies Ltd.  Cheshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Viapath Analytics, Toxicology Unit Department of Clinical Biochemistry, King's College Hospital NHS Foundation Trust  London UK"},{"name":"Pharmaceutical Sciences Clinical Academic Group King's College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181dad1fb"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000231"},{"key":"e_1_2_8_5_1","volume-title":"The Maudsley Prescribing Guidelines","author":"Taylor D","year":"2015"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC\u2010MS\/MS","volume":"75","author":"Matuzewski BK","year":"2003","journal-title":"Anal Chem"},{"key":"e_1_2_8_7_1","first-page":"145","article-title":"LC\u2010MS\/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood","volume":"229","author":"Fisher DS","year":"2013","journal-title":"For Sci Int"},{"key":"e_1_2_8_8_1","first-page":"151","article-title":"Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum","volume":"229","author":"Fisher DS","year":"2013","journal-title":"For Sci Int"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:25:40Z","timestamp":1760372740000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/dta.2223"],"URL":"https:\/\/doi.org\/10.1002\/dta.2223","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}